NCT06392841 2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
10 trialsNCT02608359 2025-02-03
A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian Participants With Metastatic, Castration Resistant Prostate Cancer
Johnson & Johnson Private Limited
Withdrawn
NCT05574712 2024-03-18
A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Withdrawn
NCT04879589 2023-04-28
Phase 1 Study of ATRS-2002 in Healthy Male Adults
Syneos Health
Phase 1 Withdrawn
NCT04296578 2021-08-12
Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone
Stanford University
Phase 1 Withdrawn
NCT03173859 2020-11-18
AERA
University of Athens
Phase 2 Withdrawn
NCT03325127 2018-10-31
Outcomes of mCRPC Patients Treated With Ra-223 Concomitant With Abiraterone or Enzalutamide- A Chart Review Study
Bayer
Withdrawn
NCT01692483 2015-12-02
Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer
Janssen Pharmaceutica
Withdrawn
NCT02159690 2015-01-26
A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy
Johns Hopkins University
Phase 2 Withdrawn
NCT01814865 2013-12-20
Anti-Proliferative Effects and Genomic Alterations of Abiraterone Acetate Compared to an Aromatase Inhibitor in Post-menopausal HR+ Operable Breast Cancer
British Columbia Cancer Agency
Phase 2 Withdrawn